Teladoc (NYSE:TDOC) exceeds Q3 2026 expectations, stock jumps 11.5%
Teladoc (TDOC) reported Q3 2026 revenue of $605.1M, beating estimates by 2.8%, with EPS of -$0.15, a 30% beat. Adjusted EBITDA was $79.36M, a 16.6% beat. Q4 revenue guidance of $592M is slightly below estimates, while full-year EPS and EBITDA guidance beat expectations. Operating margin improved to -4.6% from -8.3% YoY, and free cash flow margin rose to 12.5% from 10.5% QoQ.
How this was made

The 30-second read
Why it matters
The earnings beat and positive guidance lifted the stock 11.5% in after‑hours trading, suggesting strong short‑term buying interest.
Market read
First‑report earnings beat for a mid‑cap telehealth firm, driving notable price movement and sector momentum.
What to watch
Potential headwinds from payer reimbursement pressures and competitive pricing.
Background
Teladoc reported Q3 2026 results with revenue of $605.1M versus $588.4M consensus and GAAP EPS of -$0.15 versus -$0.21 consensus.
Ticker impact
Q3 2026 results beat revenue and EPS estimates, prompting an 11.5% stock jump.
likely continued upside as market prices in the earnings beat and raised guidance.
Both top‑line and EPS exceeded consensus, and guidance for Q4 and FY remains above estimates, supporting further buying.
Market effects
Telehealth sector may see broader rally on strong earnings from a leading player.
U.S. market sentiment boosted by a mid‑cap tech earnings beat.
Highlights growing demand for virtual care, potentially influencing global health‑tech investors.
Counterpoint
If guidance falls short of longer‑term growth expectations, the rally could be short‑lived.
Key entities
- companyTeladoc Health, Inc.
Provider of virtual healthcare services.
